F-34 | Types of Thromboembolic Events and their Outcomes Among Patients with Active Lung Cancer

Lung cancer is a well-known prothrombotic state. The incidence of various venous thromboembolic events (VTE) & their effects on in-patient outcomes of lung cancer patients is under-studied. We aim to investigate this relationship. The National Readmission Database (2016-2020) was queried to identify all-cause admissions for patients with a history of lung cancer. A Propensity Score Matching (PSM) model, matched patients with history of lung cancer to patients with any other malignancy. Pearson's x2 test was applied to the PSM-matched cohorts to compare outcomes. Among 4 million all-cause hospitalizations for active lung cancer patients, about 6.6% suffered a VTE. The majority had acute PE (3%), followed by DVT (2.4%) and DVT with PE (1.1%). On a propensity-matched & multivariate analysis, patients with lung cancer have a higher incidence of acute PE (3.6% vs 1.6%, aOR: 2.30), DVT (3% vs 2.6%, aOR: 1.24) & DVT with PE (1.5% vs 0.8%, aOR: 1.85) [p <0.001]. Among different VTEs, the mortality was highest for acute PE (aOR: 1.81), followed by DVT with PE (aOR: 1.66) & DVT (aOR: 1.64) [p <0.001]. Resource utilization is also higher in lung cancers complicated by VTE, with patients suffering a DVT having the highest LOS (7 vs 4 days) & total cost of hospitalization ($21,727 vs $14,380) [p<0.001]. The readmission rates were higher for DVT compared to PE at 90-day intervals (34.6% vs 33.4, p: 0.001). The rates of venous thromboembolism were significantly higher in lung cancer when compared to all other cancer patients. The mortality was highest for PE in this cohort, while healthcare-related burden and readmission rates were higher for DVT.